Advaxis Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Advaxis in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Advaxis stock.
View analyst ratings for Advaxis or view top-rated stocks.

Wall Street analysts have given Advaxis a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Advaxis wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Advaxis saw a decline in short interest in the month of June. As of June 15th, there was short interest totaling 4,420,000 shares, a decline of 23.1% from the May 31st total of 5,750,000 shares. Based on an average daily volume of 9,790,000 shares, the short-interest ratio is presently 0.5 days.
View Advaxis' Short Interest.

Advaxis is scheduled to release its next quarterly earnings announcement on Thursday, September 9th 2021.
View our earnings forecast for Advaxis.

Advaxis, Inc. (NASDAQ:ADXS) posted its earnings results on Sunday, June, 13th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.01. The biotechnology company had revenue of $1.38 million for the quarter.
View Advaxis' earnings history.

Advaxis' stock was trading at $0.6666 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ADXS shares have decreased by 37.4% and is now trading at $0.4171.
View which stocks have been most impacted by COVID-19.

1 brokerages have issued 1-year target prices for Advaxis' stock. Their forecasts range from $2.25 to $2.25. On average, they anticipate Advaxis' stock price to reach $2.25 in the next twelve months. This suggests a possible upside of 439.4% from the stock's current price.
View analysts' price targets for Advaxis or view top-rated stocks among Wall Street analysts.

Some companies that are related to Advaxis include Fulcrum Therapeutics (FULC), Kamada (KMDA), Enochian Biosciences (ENOB), Immunic (IMUX), Chiasma (CHMA), Cogent Biosciences (COGT), Tonix Pharmaceuticals (TNXP), Adicet Bio (ACET), Sol-Gel Technologies (SLGL), Sensei Biotherapeutics (SNSE), Trevena (TRVN), Kala Pharmaceuticals (KALA), CorMedix (CRMD), Galera Therapeutics (GRTX) and BELLUS Health (BLU).
View all of ADXS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Advaxis investors own include Inovio Pharmaceuticals (INO), Madrigal Pharmaceuticals (MDGL), Merck & Co., Inc. (MRK), Anavex Life Sciences (AVXL), VistaGen Therapeutics (VTGN), Novavax (NVAX), (CELG), Highpower International (HPJ), OPKO Health (OPK) and Athersys (ATHX).

Advaxis trades on the NASDAQ under the ticker symbol "ADXS."

Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ADXS stock can currently be purchased for approximately $0.42.

Advaxis has a market capitalization of $60.75 million and generates $250,000.00 in revenue each year.

Advaxis employs 17 workers across the globe.

The official website for Advaxis is www.advaxis.com.

Advaxis is headquartered at 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540.

Advaxis' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company can be reached via phone at 609-452-9813 or via email at [email protected]